Paul Stamets on health: what the evidence says · JRE #1385

What the evidence says 01 / RECORD

Stamets describes deciding that a documented child fatality linked to baeocystin was a "false positive" and "bad science," then self-administering the compound based on that personal judgment rather than any toxicological study. Baeocystin is a minor, poorly studied alkaloid found alongside psilocybin and psilocin in some Psilocybe and related mushroom species; controlled pharmacological and toxicological data on baeocystin in humans are essentially absent from the peer-reviewed literature. A 2014 toxicology review of mushroom poisoning documents that psilocybin-containing mushrooms cause hallucinations, agitation, seizures, and hyperthermia in children, while severe organ failure and fatalities in pediatric mushroom poisonings are attributed overwhelmingly to misidentified amatoxin-containing species (e.g., Amanita phalloides) rather than to psilocybin or baeocystin specifically; it does not identify any baeocystin-specific fatality, so it neither confirms nor refutes the child-death account Stamets references. A 2022 review of psychedelic adverse effects further notes that much of the safety evidence base for rarer psychedelic compounds remains anecdotal rather than systematically studied. Because no controlled toxicity data on baeocystin exist, Stamets's uncontrolled self-experiment cannot establish the compound is safe, and his dismissal of a documented fatality as a "false positive" is a personal assertion unsupported by published toxicological evidence rather than a scientifically validated correction.